M. Azémar
Impact in
-
- Immunotherapy and Immune Responses
- Toxin Mechanisms and Immunotoxins
-
- CAR-T cell therapy research
- Vascular Tumors and Angiosarcomas
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Transgenic Plants and Applications 3
- Microbial Inactivation Methods 2
- Cancer Research and Treatments 2
-
- Toxin Mechanisms and Immunotoxins 3
- Co-authors
- Winfried S. Wels (4 shared papers)Bernd Groner (4 shared papers)Mathias Schmidt (4 shared papers)Elisabeth Stöcklin (2 shared papers)Wanja M. Bernhardt (4 shared papers)Reinhard Henschler (4 shared papers)A. Spyridonidis (4 shared papers)Uwe Altenschmidt (1 shared paper)
- Journals
- Blood (4 papers)The Prostate (1 paper)Investigational New Drugs (1 paper)Mycoses (1 paper)Prostate Cancer and Prostatic Diseases (1 paper)
- Partner nations
- GermanyFranceUnited States
In The Last Decade
M. Azémar
15 papers receiving 240 citations
Peers
Comparison fields: 5 of 44
- Immunology 84
- Oncology 102
- Pulmonary and Respiratory Medicine 57
- Biotechnology 15
- Hematology 18
Countries citing papers authored by M. Azémar
This map shows the geographic impact of M. Azémar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Azémar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Azémar more than expected).
Fields of papers citing papers by M. Azémar
This network shows the impact of papers produced by M. Azémar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Azémar. The network helps show where M. Azémar may publish in the future.
Co-authors
The 25 scholars most cited alongside M. Azémar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. | 1998 | 43 |
| 2 | 2005 | 43 | |
| 3 | 2007 | 40 | |
| 4 | 1998 | 33 | |
| 5 | 1991 | 26 | |
| 6 | 2010 | 19 | |
| 7 | 1999 | 10 | |
| 8 | 2009 | 8 | |
| 9 | 1999 | 6 | |
| 10 | 2009 | 4 | |
| 11 | 1998 | 4 | |
| 12 | 1998 | 4 | |
| 13 | 1999 | 2 | |
| 14 | [26-year-old patient with space-occupying lesion of the cervix, pulmonary coin lesion and eosinophilia]. | 1995 | 1 |
| 15 | Analysis of c-sis/PDGF-B mRNA expression in megakaryocytic cells of patients with myeloproliferative disorders. | 1990 | 1 |
About M. Azémar
M. Azémar is a scholar working on Biotechnology, Immunology, Pulmonary and Respiratory Medicine, Oncology and Hematology, having authored 15 papers that have together received 244 indexed citations. Recurring topics across this work include Transgenic Plants and Applications (3 papers), Toxin Mechanisms and Immunotoxins (3 papers), Hematopoietic Stem Cell Transplantation (2 papers), Cancer Cells and Metastasis (2 papers), Microbial Inactivation Methods (2 papers), Cancer Research and Treatments (2 papers), Sarcoma Diagnosis and Treatment (1 paper) and Antifungal resistance and susceptibility (1 paper). The work is most often cited by research in Immunology (84 citations), Oncology (102 citations), Pulmonary and Respiratory Medicine (57 citations), Biotechnology (15 citations) and Hematology (18 citations). M. Azémar has collaborated with scholars based in Germany, France and United States. Frequent co-authors include Winfried S. Wels, Bernd Groner, Mathias Schmidt, Elisabeth Stöcklin, Wanja M. Bernhardt, Reinhard Henschler, A. Spyridonidis, Uwe Altenschmidt, Lothar Kanz and Marius Horger. Their work appears in journals such as Blood, The Prostate, Investigational New Drugs, Mycoses and Prostate Cancer and Prostatic Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.